SynthesisCurrent opinion in urology2019
Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications.
Synthesis in Current opinion in urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses.bioRxiv : the preprint server for biology · 2026Article
- Article
- Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.Frontiers in immunology · 2026Review
- Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity.Cancer cell · 2025Article
- Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice.Scientific reports · 2025Article
- Dendritic cell-derived exosomes as anti-cancer cell-free agents: new insights into enhancing immunogenic effects.Frontiers in immunology · 2025Review
- Review
- Microbial Therapeutics in Oncology: A Comprehensive Review of Bacterial Role in Cancer Treatment.Cureus · 2024Review
- BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.Current oncology (Toronto, Ont.) · 2024Review
- Drug Repurposing in the Chemotherapy of Infectious Diseases.Molecules (Basel, Switzerland) · 2024Review
- Re: Non-progressive breast carcinomas detected at mammography screening: a population study-a model test or a novel test of cancer regression?Breast cancer research : BCR · 2023Article
- Review
- FGFBP1 as a potential biomarker predicting bacillus Calmette-Guérin response in bladder cancer.Frontiers in immunology · 2022Article
- Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.Vaccine · 2021Review
- Bladder tumor ILC1s undergo Th17-like differentiation in human bladder cancer.Cancer medicine · 2021Observational
- Article
- Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.Vaccines · 2021Article
- Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy.Pharmaceutics · 2021Review
- High-grade T1 Urothelial Carcinoma: Where Do We Stand?Current urology reports · 2019Review
- Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management.Academic pathologyArticle
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewBacillus Calmette-Guérin (BCG) is the standard immune therapy for nonmuscle invasive bladder cancer. A systematic review of published articles regarding BCG treatment of bladder cancer was conducted and a commentary of these is provided to gain a perspective of the current major developments in the field. RECENT
findingsSeveral BCG strains are utilized worldwide. As the understanding of genetic and phenotypic differences in these strains is elucidated, inquiries into the potential clinical effects of these various strains have been studied. Data suggest that some strains could be more effective than others but further study is needed. Although response to BCG is heterogenous, current clinical practice does not incorporate use of biomarkers to delegate treatment selection. Thus, biomarker prediction is an important area of research in this area. Novel urine and tissue markers show promise in this endeavor. Notable publications also include mechanistic studies showing a role for T cells, natural killer cells, mast cells, and granulocytes in BCG's antitumor efficacy. SUMMARY: Significant developments have occurred in understanding BCG's response and mechanism of action, which remains incompletely understood. Future work includes efforts to create recombinant BCG strains to decrease side effects, repeated instillations, and increase overall efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.